Immuno-Oncology

A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy (2021) Choueiri TK, Atkins MB, Rose TL, Alter RS, Yawen J, Niland K, Wang Y, Arbeit R, Parasuraman S, Gan L, McDermott DF Investigational New Drugs

LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial (2021) Dowlati A, Jarvey RD, Carvajal RD, Hamid O, Klempner SJ, Wook Kauh JS, Peterson DA, Yu D, CHapman SC, Szpurka AM, Carlsen M, Quinlan T, Wesolowski R Investigational New Drugs

Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC (2021) Ross-Macdonald P, Walsh AM, Chasalow SD, Ammar R, Papillon-Cavanagh S, Szabo pm, Choueiri TK, Sznol M, Wind-Rotolo M Journal for Immunotherapy for Cancer

Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma (2021) Lee CH, Motzer RJ, Glen H, Michaelson MD, Larkin J, Minoshima Y, Kanekiyo M, Ikezawa H, Sachdev P, Dutcus CE, Funashashi Y, Voss MH British Journal of Cancer

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results (2021) Advani R, Moskowitz AJ, Bartlett NL, Vose J, Ramchandren R, Feldman T, LaCasce AS, Christian B, Ansell SM, Moskowitz CH, Brown L, Zhang C, Taft D, Ansari S, Sacchi M, Ho L, Herrera AF Blood

Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study (2021) Greil R, Tedeschi A, Moreno C, Anz B, Larratt L, Simkovic M, Gill D, Gribben JG, Flinn IW, Wang Z, Cheung LWK, Nguyen AN, Zhou C, Styles L, Demirkan F Annals of Hematology

Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab teserine in patients with small cell lung cancer (2021) Calvo E, Spira A, de Miguel M, Kondo S, Gazzah A, Millward M, Prenen H, Rottey S, Warburon L, Alanko T, Cassier PA, Yoh K, Italiano A, Moreno V, Peltola K, Seto T, Toyozawa R, Afar DE, Englert S, Komarnitsky P, Lambert S, Parikh A, Vosganian G, Gao B Cancer Treatment and Research Communities

First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma (2021) Italiano A, Cassier PA, Lin CC, Alanko T, Peltola KJ, Gazzah A, Shiah HS, Calvo E, Cervantes A, Roda D, Tosi D, Gao B, Millward M, Warburton L, Tanner M, Englert S, Lambert S, Parikh A, Afar DE, Vosganian G, Moreno V Cancer Immunology, Immunotherapy

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma (2020) Timmerman J, Herbaux C, Ribrag V, Zelenetz AD, Houot R, Neelapu SS, Logan T, Lossos IS, Urba W, Salles G, Ramchandren R, Jacobson C, Godwin J, Carpio C, Lathers D, Liu Y, Neely J, Suryawanshi S, Koguchi Y, Levy R American Journal of Hematology

Elevated serum interlukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors (2020) Schalper KA, Carleton M, Zhou M, Chen T, Feng Y, Huang SP, Walsh AM, Baxi V, Pandya D, Baradet T, Locke D, Wu Q, Reilly TP, Phillips P, Nagineni V, Gianino N, Gu J, Zhao H, Perez-Gracia JL, Snmamed MF, Melero I Nature Medicine

Model informed dosing regimen and phase I results of the anti-PD-1 antibody budigalimab (ABBV-181) (2020) Powderly J, Spira A, Kondo S, Doi T, Luke JL, Rasco D, Gao B, Tanner M, Cassier PA, Gazzah A, Italiano A, Tosi D, Afar DE, Parikh A, Engelhardt B, Englert S, Lambert SL, Kasichayanula S, Mensing S, Menon R, Vosganian G, Tolcher A Clinical and Translational Science

Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes (2020) Adams SF, Grimm AJ, Chiang CLL, Mookerjee A, Flies D, Jean S, McCann GA, Michaux J, Pak H, Huber F, Neal C, Dangaj D, Bassani-Sternberg M, Rusakiewicz S, Facciabene A, Coukos G, Gimotty PA, Kandalaft LE Journal for ImmunoTherapy of Cancer

Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,30dioxygenase 2, in patients with advanced solid tumors (2020) Naing A, Eder JP, Piha-Paul SA, Gimmi C, Hussey E, Zhang S, Hildebrand V, Hosagrahara V, Habermehl C, Moisan J, Papadopoulos KP Journal for ImmunoTherapy of Cancer

IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. (2019) Chan LC, Li CW, Xia W, Hsu JM, Lee HH, Cha JH, Wang HL, Yang WH, Yen EY, Chang WC, Zha Z, Lim SO , Lai YJ, Liu C, Liu J, Dong Q, Yang Y, Sun L, Wei Y, Nie L, Hsu JL, Li H, Ye Q, Hassan MM, Amin HM, Kaseb AO, Lin X, Wang SC, Hung MC The Journal of Clinical Investigation

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors (2019) Piha-Paul SA, Hann CL, French CA, Cousin S, Brana I, Cassier PA, Moreno V, de Bono JS, Duckworth Harward S, Ferron-Brady G, Barbash O, Wyce A, Wu Y, Horner T, Annan M, Parr NJ, Prinjha RK, Carpenter CL, Hilton J, Hong DS, Hass NB, Markowski MC, Dhar A, O'Dwyer PJ, Shapiro GI JNCI Cancer Spectrum

A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. (2019) Rammensee HG, Wiesmuller KH, Chandran PA, Zelba H, Rusch E, Gouttefangeas C, Kowalewski DJ, Di Marco M, Haen SP, Walz JS, Gloria YC, Bodder J, Schertel JM, Tunger A, Muller L, Kiebler M, Wehner R, Schmitz M, Jakobi M, Schneiderhan-Marra N, Klein R, Laske K, Artzner K, Backert L, Schuster H, Schwenck J, Weber ANR, Pichler BJ, Kneilling M, la Fougere C, Forchhammer S, Metzler G, Bauer J, Weide B, Schippert W, Stevanovic S, Loffler MW Journal for ImmunoTherapy of Cancer

Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma. (2019) Wang R, Zheng J, Shao X, Ishii Y, Roy A, Bello A, Lee R, Zhang J, Wind-Rotolo M, Feny Y Journal for ImmunoTherapy of Cancer

Blockade of placental growth factor reduces vaso-occlusive complications in murine models of sickle cell disease (2018) Gu JM, Yuam S, Sim D, Abe K, Liu P, Rosenbruch M, Bringmann P, Kauser K Experimental Hematology 2018

Standardized Immunomonitoring: Separating the Signals from the Noise (2018) Duffy D Trends in Biotechnology

PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients (2018) Naing A, Infante JR, Papadopoulos KP, Chan IH, Shen C, Ratti NP, Autio KA, Wong DJ, Patel MR, Ott PA, Falchook GS, Pant S, Hung A, Pekarek KL, Wu V, Adamow M, McCauley S, Mumm JB, Wong P, Van Vlasselaer P, Levegue J, Tannir NM, Oft M Cancer Cell

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy (2017) Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, Kirkwood JM, Miller LD, Schendel DJ, Tanneau I, Wigginton JM and Butterfield LH J Immunother Cancer

The Orally Available Selective Axl Inhibitor BGB324 Induces Diversification of the Immune Repertoire and Specific Changes in Plasma Biomarker Profiles (2017) Loges S, Gjertsen BT, Heuser M, Chromik J, Ben-Batalla I, Akyuz N, Micklem D, Brown A, Lorens J, Yule M, Kebenko M, Janning M, Binder M, Fiedler W, Cortes J Blood

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma (2016) Choueiri TK, Fishman M, Escudier B, McDermott DF, Drake CG, Kluger HM, Stadler WM, Perez-Gracia JL, McNeel DG, Curti BD, Harrison MR, Plimack ER, Appleman L, Fong L, Albiges L, Cohen LJ, Young TC, Chasalow SD, Ross-MacDonald P, Srivastava S, Jure-Kunkel M, Kurland JF, Simon JS, Sznol M Clinical Cancer Research

Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (Am0010) in Patients with Advanced Solid Tumors (2016) Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, Falchook GS, Pant S, Whiteside M, Rasco DR, Mumm JB, Chan IH, Bendell JC, Bauer TM, Colen RR, Hong DS, Van Vlasselaer P, Tannir NM, Oft M, Infante JR Journal of Clinical Oncology

Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab (2015) Sznol M, Fishman M, Escudier B, McDermott DF, Kluger H, Stadler WM, Perez-Gracia J, McNeel DG, Curti BD, Harrison MR, Plimack ER, Appleman L, Fong L, Drake CG, Young TC, Chasalow SD, Ross-MacDonald P, Simon JS, Walker D, Choueiri TK J Immunother Cancer

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. (2014) Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ. Nature. 2014 Nov 26;515(7528):558-62. doi: 10.1038/nature13904.

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. (2014) Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Nature. 2014 Nov 26;515(7528):563-7. doi: 10.1038/nature14011.